F10 and cancer: Both the efficacy and safety of rivaroxaban compared to warfarin showed non-inferiority in AF patients with cancer, as demonstrated in the sub-study of Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET-AF) of Chen ST et al. A total of 640 cancer patients (rivaroxaban group: 309; warfarin group: 331) were considered for analyses followed for a median time of 1.9 years.